Abstract
Intracellular calcium plays a pivotal role in the maintenance of smooth muscle tone (1). It was not surprising therefore that calcium entry blockers have met a widespread success in the treatment of hypertension, a disease characterized by peripheral arteriolar vasoconstriction (2). However, it was soon found that the antihypertensive action of calcium entry blockers was due not only to the peripheral vasodilation (3–7) but also to other effects including natriuresis (8–10) and alteration of autonomic nervous system (11,12). Despite this multifaceted antihypertensive effect, the ability to reduce peripheral vascular resistance remained the most widely recognized mediator of blood pressure control by this class of drugs. Not only peripheral vascular resistance was found to be reduced during therapy with various CEB, but also forearm blood flow increased significantly after acute and chronic nifedipine treatment (13). It is the mechanism by which this decrease in vascular smooth muscle tone is achieved that needs further explanation.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Rasmussen, H. Ann. Intern. Med. 98 (Pt. 2): 809–816, 1983.
Tarazi, R.C., Ibrahim, M.M., Dustan, H.P. and Ferrario, C.M. Circ. Res. (Suppl. I) 34: 213–221, 1974.
Aoki, K., Kondo, S., Mochizuki, A., Yoshida T., Kato, S., and Takikawa, K. Am. Heart J. 96: 218–226, 1978.
Olivari, M.T., Bartorelli, C., Polese, A., Fiorentini, C., Maruzzi, P., and Guazzi, M. Circulation 59: 1056–1062, 1979.
Pederson, O.L. Acta Pharmacol. Toxicol. 49 (Suppl. II): 1, 1981.
Fouad, F.M., Aboul-Khair, M., Tarazi, R.C. J. Cardiovasc. Pharmacol. 4: S383–S386, 1982.
Tarazi, R.C, Aboul-Khair, M., and Kobayashi, K. In: Nitrendipine (Eds. A. Scriabine, S. Vanov, and K. Deck), Urban and Schwarzenberg, Baltimore-Munich, 1983, pp. 251–270.
Leonetti, G., Cuspidi, C., Smapieri, L., Terzoli, L., Zanchetti, A. J. Cardiovasc. Pharmacol. 4: S319–S324, 1982.
Garthoff, B., Knorr, A., Thomas, G., Kazda, S. Biochem, Pharmacol. 18: 3015–3016, 1982.
Luft, F.C., Aronoff, G.R., Sloan, R.S., Fineberg, N.S., and Weinberger, M.H. Hypertension 7: 438–442, 1985.
Henry, P.D. In: Calcium Blockers, Mechanisms of Action and Clinical Applications (Eds. S.F. Flaim and R. Zelis), Urban & Schwarzenberg, Baltimore-Munich, 1982, pp 135
McLeay, R.A.B., Stallard, T.J.,Watson, R.D.S., and Littler, W.A. Circulation 67: 1084, 1983.
Pederson, L.O., Mikkelsen, E. Eur. J. Clin. Pharmacol. 14: 375, 1978.
Fleckenstein, A. Calcium Antagonism in Heart and Smooth Muscle, John Wiley & Sons, New York, 1983, pp. 209–285.
Casteels, R. Chest 78 (Suppl.): 150, 1978.
Van Breemen, C., Aaronson, P., Loutzenhiser, R., Meisheri, K. Chest 78 (Suppl.): 157, 1978.
Van Meel, J.C.A., De Jonge, A., Kalkman, H.O., Willfert, B., Timmermans, P.B.M.W.M., Van Zwieten, P.A. Eur. J. Pharmacol. 69: 205–208, 1981a.
Van Zwieten, P.A.,Van Meel, J.C.A. and Timmermans, P.B.M.W.M. Hypertension 5 (Suppl. II): 8–17, 1983.
Pedrinelli, R. and Tarazi, R.C. Circulation 69: 1171–1176, 1984.
Pedrinelli, R. and Tarazi, R.C. J. Pharm. & Exp. Therap. 233: 643–649, 1985.
Cauvin, C., Loutzenhiser, R., Hwang, O. and Van Breeman, C. Eur. J. Pharmacol. 84: 233–235, 1982.
Awad, R., Payne, R. and Deth, R.C. J. Pharmacol. & Exp Therap. 227: 60–67 1983.
Janssens, W. and Verhaeghe, R. J. Physiol. (London) 347: 525–532, 1984.
DeMey, J. and Vanhoutte, P.M. Circ. Res. 48: 875–884, 1981.
Muller-Schweinitzer, E. Naunyn-Schiedeberg’s Arch. Pharmacol. 324: 64–69, 1983.
Beckering, J.J., Thoolen, M.J.M.C., De Jonge, A., Willfert, B., Timmermans, P.B.M.W.M., and Van Zwieten, P.A. J. Pharmacol. Exp. Therap. 229: 515–521, 1984.
Langer, S.Z., Shepperson, N.B. Br. J. Pharmacol. 74: 942, 1981.
Van Meel, J.C.A., De Zoeten, K., Timmermans, P.B.M.W., Van Zwieten, P.A. J. Auton. Pharmacol. 2: 13, 1982.
Timmermans, P.B.M.W., De Jonge, A., Van Meel, J.C.A., Mathy, M.J., and Van Zwieten, P.A. J. Cardiovasc. Pharmacol. 5: 1, 1983.
Llenas S. and Massingham, R. Eur. J. Pharmacol. 87: 53, 1983.
Kobinger, W., Lillie, C. and Pichler, L. Circ. Res. (Suppl. 1) 46: 21–25, 1980.
Folkow, B. Circulation 21: 760–768, 1960.
Guazzi, M.D., Fiorentini, C., Olivari, M.T., Bartorelli, A., Necchi, G. and Polese, A. Circulation 61, 913–919, 1980.
Fouad, F.A., Pedrinelli, R., Bravo, E.L., Abi-Samra, F., Textor, S.C. and Tarazi, R.C. Clin. Pharmacol. & Therap. 35: 768–775, 1984.
Brown, A.M. Circ. Res. 46: 1–10, 1980.
Watson, R.D.S., Stallard, T.J. and Littler, W.A. Clin. Sci. 57: 241, 1979.
Millard, E.W., Lathrop, D.A., Grupp, G., Ashraf, M., Grupp, I.L. and Schwartz, A. Am. J. Cardiol. 49: 499–505, 1982.
Tarazi, R.C. Cardiovasc. Med. 3: 1125–1131, 1978.
Tarazi, R.C. and Fouad, F.M. J. Hypertension 3 (Suppl. 2): S27–32, 1985.
Kazda, S., Garthoff, B., Meyer, H., Schlossmann, K., Stoepel, K., Towart, R., Vater, W. and Wehinger, E. Arzneim, Fosch. 30: 2144–2162, 1980.
Triggle, D.J. In: New Perspectives on Calcium Antagonists (Ed. G.B. Weiss), American Physiological Society, Bethesda, 1981, pp. 1–18.
Dargie, H., Rowland E. E. and Krickler, D. Br. Heart J. 468: 8–16, 1981.
Leon M.B., Rosing, D.R., Bonow, R.O., Lipson, L.C. and Epstein, S.E. Am. J. Cardiol. 48: 131–139, 1981.
Bela Subramanian, V., Bowles, M.J., Davies, A.B. and Raftery, E.B. Am. J. Cardiol. 49: 125–132, 1982.
Goldstein, R.E., Beiser, G.D., Stampfer, M. and Epstein, S.E. Circ. Res. 36: 571–578, 1975.
Fifer, M.A., Colucci, W.S., Lorell, B.H., Jaski, B.E. and Barry, W.H. J. Am. Coll. Cardiol. 5: 731–737, 1985.
Elkayam, U., Weber, L., Torkan, B., Berman, D. and Rahimtoola, S.H. Am. J. Cardiol. 52: 1041–1045, 1983.
Prida, X.E., Kubo, S.H., Laragh, J.H. and Cody, R.J. Am. J. Med. 75: 795–800, 1983.
Miller, A.B., Conetta, D.A. and Bass, T.A. Am. J. Cardiol. 55: 1359–1362, 1980.
Olivari, M.T., Levine, T.B. and Cohn, J.N. J. Cardiovasc. Pharmacol. 6 (Suppl. 7): S1002–S1005, 1984.
Kubu, S.H., Fox, S.C, Prida, X.E. and Cody, R.J. Am. Heart J. 10: 1032–1034, 1985.
Lahiri, A., Tovey, J., Kohli, R.S., Robinson, C.W., Caruana, M.P., Harlow, B.J. and Raftery, E.B. Postgraduate Med. Journal 60 (Suppl 4): 35–38, 1984.
Given, B.D., Lee, T.H., Stone, P.H. and Dzau, V.J. Arch. Intern. Med. 145: 281–285, 1985.
Tweddel, A.C. and Hutton, I. Eur. Heart J. 7: 54–60, 1986.
Kobayashi, K. and Tarazi, R.C. Hypertension 5 (Suppl II): II-45 - II-51, 1983.
Cantelli, I., Pavesi, P.C., Parchi, C, Naccarella, F. and Bracchetti, D. Am. Heart J. 106: 308–315, 1983.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Fouad-Tarazi, F., Pedrinelli, R. (1987). Interaction of Calcium Entry Blockers and Adrenergic System in Hypertension and Heart Failure. In: Beamish, R.E., Panagia, V., Dhalla, N.S. (eds) Pharmacological Aspects of Heart Disease. Developments in Cardiovascular Medicine, vol 68. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2057-9_8
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2057-9_8
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9222-7
Online ISBN: 978-1-4613-2057-9
eBook Packages: Springer Book Archive